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Cardiometabolic diseases can be present long before becoming clinically apparent. Accurate predictors of
disease are of particular importance since the delay or prevention of morbidity is possible via pharmacolog-
ical and behavioral interventions. Metabolomics is increasingly applied to biomarker discovery. Understand-
ing howmetabolites relate with established cardiometabolic risk factors is critical in evaluating their potential
value as clinical biomarkers. Large epidemiological cohort studies can assess whether metabolite bio-
markers improve upon existing diseasemarkers. Furthermore, experimental work inmodel systems and inte-
gration with other functional genomic approaches will facilitate the discovery of causal links between select
biomarkers and disease pathogenesis.The Need for New Cardiometabolic Biomarkers
Cardiometabolic diseases are difficult for physicians to manage
because they can be present for years before becoming clinically
apparent. For example, patients presenting with acute coronary
syndromes due to focal plaque instability often have extensive
subclinical atherosclerosis in other vascular beds. Similarly, by
the time the diagnosis of type 2 diabetes mellitus (DM) is made
based on hyperglycemia, significant b cell insufficiency has often
occurred. Although knowledge of conventional risk predictors
can help in the detection of future disease, prediction remains
imperfect, mirroring our incomplete understanding of underlying
mechanisms. Despite strong statistical associations with out-
comes, new biomarkers often contribute less than expected to
the accuracy of risk models because many report on the same
pathways as preexisting disease markers. As highlighted in this
review, there is a mandate for orthogonal (i.e., uncorrelated) dis-
easebiomarkers that provide additional clinical information along
new biological axes. A robust set of predictors for identifying at-
risk individuals is of particular importance because the delay or
prevention of diseases such as atherosclerosis or DM is now
possible via pharmacological interventions, such as statins and
metformin, aswell as bybehavioral approaches, includingweight
loss and exercise interventions. New predictors may also identify
patients likely to respond to specific interventions, moving to-
ward a goal of more personalized medicine (Loscalzo, 2012).
One avenue for the identification of novel risk markers is being
opened by the global analysis of the human metabolome. While
decades of research in biochemistry, nutrition, and physiology
have revealed specific metabolic pathways, systematic surveys
of pathways altered in human disease states, such as athero-
sclerosis or DM, are now possible. An emerging set of metabolite
profiling capabilities, based on techniques such as mass spec-
trometry and nuclear magnetic resonance (NMR) spectroscopy,
enable the monitoring of hundreds of analytes from biological
samples (metabolomics or metabonomics). These technologies
promise to transform our ability to profile samples, with the goal
of illuminating biology and discovering valuable clinical bio-
markers.
From a clinical perspective, biomarkers can serve a variety of
functions, corresponding to different stages in disease evolution.Biomarkers can assist in the care of patients without apparent
disease (screening biomarkers), with suspected disease
(diagnostic biomarkers), or with progression or remission of
overt disease (prognostic biomarkers). Biomarkers that partici-
pate in disease pathways are the most likely candidates for dis-
ease surrogates—substitutes for a clinical endpoint. A surrogate
endpoint might predict clinical benefit (or harm) of a given thera-
peutic, with an ultimate goal of facilitating the drug discovery
process.
In the case of coronary heart disease, the majority of individ-
uals have only one or none of the classic cardiovascular risk fac-
tors (Khot et al., 2003), which underscores the need for screening
biomarkers in particular. The majority of current biomarkers for
cardiovascular screening fall along pathways, such as inflamma-
tion and cholesterol biosynthesis, already known to be associ-
ated with cardiovascular disease. Similarly, many biomarkers
for diabetes solely interrogate glucose homeostasis. Conse-
quently, available biomarkers often provide information that is
correlated with what is already known or being measured.
Although correlated biomarkers can underscore the importance
of a biological pathway, they may not provide a substantial in-
crease in diagnostic or predictive value.
This point has been highlighted by recent investigations.Wang
and colleagues explored factors that influence whether new bio-
markers can add to diagnosis and risk prediction above and
beyond establishedmarkers (Wang et al., 2006). They performed
a simulation based on adding 1 to 100 hypothetical biomarkers
to a traditional risk model for cardiovascular disease (Figure 1).
When assessing biomarker sensitivity and specificity, traditional
risk models (including cholesterol concentrations, age, and hy-
pertension) have an approximate area under the curve (AUC) of
0.75 across populations. For their simulation, each of the hypo-
thetical biomarkers had a similar magnitude of association with
cardiovascular events similar to established cardiovascular bio-
markers such as C-reactive protein (CRP) or B-type natriuretic
peptide (BNP). They demonstrated that a key determinant of
improvement in the c-statistic is the degree of correlation be-
tween biomarkers. With a set of biomarkers that has a mean
marker-marker correlation of r = 0.4 (moderately correlated),
>50 biomarkers are needed before the c-statistic is increasedCell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc. 43
Figure 1. Increment in Discrimination from Adding Hypothetical
Biomarkers According to the Degree of Marker-Marker Correlation r
The simulated hazards ratio for the outcome is 1.35 per SD increment in the
biomarker. The y axis shows the c-statistic from a model containing traditional
risk factors plus a variable number of simulated biomarkers (x axis), eachwith a
fixed association with the outcome.
Figure 2. Intercorrelation of Circulating Metabolites
Data from 200 normal individuals from the Framingham Heart Study.
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tion is r = 0.05 (weakly correlated), <10 biomarkers are needed
to raise the c-statistic by 0.05. Thus, new methodologies must
be brought to bear to identify signals across different physiolog-
ical axes to improve disease prediction.
To illustrate the potential contribution of metabolite profiling to
clinical biomarker discovery, Figure 2 depicts the correlations
for 48 plasma metabolite concentrations in approximately 200
fasting individuals in the population-based Framingham Heart
Study (FHS). Mean correlations within groups of molecules
were highest for urea-cycle metabolites (r = 0.49), metabolites
involved in nucleotide metabolism (r = 0.38), amino acids (r =
0.34), and methyl-transfer metabolites (r = 0.34). Correlations
across other metabolites or groups of metabolites were far
weaker. As more metabolites are measured in large cohorts,
similar correlation clusters (both expected and unexpected)
are likely to emerge. Understanding how metabolites relate
with each other and with established risk markers will be impor-
tant in assessing their value as potential biomarkers and may
also lead to previously unappreciated connections between
metabolic pathways.
Incorporation of Metabolomics Platforms for Biomarker
Discovery
The limitations of currently available biomarkers for screening
thus underscores the importance of identifying uncorrelated or
orthogonal biomarkers associated with novel disease pathways.
Emerging technologies are beginning to permit the systematic,
unbiased characterization of variation in genes, RNA, proteins,
and metabolites associated with disease conditions. Interroga-
tion of metabolites as disease markers is particularly attractive
since small molecules are most proximal to any disease pheno-
type.
During the 1970’s, Arthur Robinson and Linus Pauling postu-
lated that the quantitative and qualitative pattern of metabolites
in biological fluids reflected the functional status of the complex
biological system from which they were derived (Pauling et al.,
1971). Concomitantly, the term metabolic profiling was intro-
duced to describe data obtained from gas chromatography
analysis of a patient sample (Horning and Horning, 1971).44 Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc.Studies of inborn errors of metabolism represent the first
applications of metabolite profiling to human diagnostics. Roe
et al. (1986) pioneered the use of mass spectrometry-based
methods for monitoring fatty acid oxidation as well as organic
and selected amino acids. In many instances, rapid identifi-
cation of inborn errors allows for dietary modulation and amelio-
ration of symptoms or disease onset. It is anticipated that a
global metabolomic analysis of aberrant pathways in more
common diseases, such as diabetes or atherosclerosis, might
similarly spotlight new biomarkers or pathways for dietary or
drug modulation.
The metabolomics approach, built upon decades of funda-
mental research in biochemistry, aims to measure the metabo-
lites present within a cell, biofluid, tissue, or organism at baseline
or in the context of a perturbed state, such as a genetic alteration
or a physiological or environmental stimulus (Oliver et al., 1998;
Nicholson et al., 1999; Fiehn, 2001). Metabolomics was initially
employed to identify seemingly silent phenotypes in model sys-
tems such as yeast. That is, biochemical profiling techniques
were used to identify the downstream functions of genes that,
when perturbed, have no apparent influence on physical charac-
teristics or behavior, upon initial routine evaluation (Griffin et al.,
2002). The reason for this powerful analytical advantage be-
comes apparent when we consider that the metabolome is the
terminal downstream product of the genome and consists of
the total complement of all the low-molecular-weight molecules
(metabolites) in a cell, biofluid, tissue, or organism required for
growth, maintenance, or normal function in a specific physiolog-
ical state (Goodacre, 2003; Goodacre et al., 2004). It could be
envisioned that metabolic perturbations developing prior to the
onset of disease symptoms (a silent phenotype) could be used
as biomarkers for screening at-risk populations or that a partic-
ular metabolic profile corresponds to specific disease states or
progression.
The metabolome itself represents an incredible variety of
chemical classes and physical properties ranging from the small,
Table 1. Metabolomics Technologies
Chromatography None Gas chromatography Liquid chromatography Other
NA ideal for volatile nonpolar
analytes
ideal for ionisable
analytes in solution
direct infusion (no
chromatography);
capillary electrophoresis;
thin-layer chromatography
Y Y
Analytical Method NMR mass spectrometry
TOF triple quadrupole ion trap
Metabolite Identification chemical shift m/z (flight time) m/z (filters for m/z) m/z (trapping frequency)
Advantages robust; no sample
destruction; no
chromatography or analyte
ionization; unambiguous
identification of abundant
analytes
mass accuracy; wide
mass range
sensitivity; can perform
MS/MS; dynamic range
sensitivity; can perform
MS/MS
Disadvantages limited sensitivity limited dynamic range;
isotopic standards required
for absolute quantitation
poor mass accuracy;
isotopic standards required
for absolute quantitation
limited dynamic range;
isotopic standards required
for absolute quantitation
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The dynamic range of metabolite concentrations exists across
orders of magnitude, varying from the picomolar to the milli-
molar. This variability in chemical property and dynamic range
provides a considerable challenge for metabolomics, especially
viewed in light of other ‘‘omic’’ techniques, such as genomics
and transcriptomics, where the chemical variations in the analy-
tes (DNA ormessenger RNA [mRNA], respectively) areminimal in
comparison. To optimize coverage of the metabolome, the use
of an extensive array of analytical techniques within the field of
metabolomics is necessary.
Metabolomic Analytical Techniques
The principle profiling technologies utilized in metabolomic
analysis are NMR spectroscopy and mass spectrometry, which
is often coupled to a prior chromatographic technique, most
commonly liquid or gas chromatography (LC or GC). However,
with an estimated 5,000 currently detectable human serum
metabolites (a number likely to increasewith advances in technol-
ogy) (Wishart et al., 2013), a comprehensivemetabolomicmap re-
mains an unattained goal. Using a combined analytical approach,
one can build a more inclusive picture of the metabolome by
overcoming the limitations of individual techniques (Table 1).
1H-Nuclear Magnetic Resonance Spectroscopy in
Metabolomics
The use of 1H-NMR spectroscopy to simultaneously detect an
array of metabolites in biological fluids was pioneered during
the early 1980’s (Nicholson et al., 1983, 1984a, 1984b; Bales
et al., 1984). NMR utilizes the magnetic properties of select
atomic nuclei (e.g., 1H, 13C, or 31P) to determine the structure
and abundance of metabolites in a biological specimen. In a
strongmagnetic field, a given NMR-active nucleus absorbs elec-
tromagnetic radiation at a characteristic frequency. Since this
NMR signal is influenced in an identifiable way by the nature of
neighboring atoms, chemical shifts in its resonance frequency
can be used to assign local molecular structure. By measuring
all frequencies, metabolite identity can be determined, thoughthis is not feasible for all compounds in a complex mixture. The
popularity of NMR spectroscopy arises from the technique’s
spectroscopic, quantitative, robust, and reproducible nature
and its low cost per sample analysis (Bothwell and Griffin,
2011). It is nondestructive, permitting multiple analyses of the
same sample. NMR is capable of absolute quantification without
the use of isotope-labeled standards. Although the majority of
NMR-based metabolomics experiments are performed on sam-
ples in the solution state, NMR has a further advantage: through
the use of high-resolution magic-angle-spinning NMR, metabo-
lites can be measured within intact tissue samples (Moestue
et al., 2011). However, a major criticism of NMR spectroscopy
in metabolomic analyses is that, compared to many other tech-
niques, it suffers from relatively poor sensitivity in the analysis of
low-abundance metabolites. The relative lack of sensitivity in
NMR analysis has limitations when it comes to biomarker dis-
covery where alterations in low-abundance metabolites may
be missed or obscured by signals from species at a higher abun-
dance. The analysis of blood plasma metabolite extracts using
1H-NMR typically detects 20–50 metabolites (Rooney et al.,
2003; Griffin et al., 2001). However, when applied to urine, the
number of metabolites observed may be double that number
(Griffin and Shockcor, 2004). High-resolution NMR using stron-
ger magnetic fields or two-dimensional NMR permits higher in-
formation content and increased analytical sensitivity, especially
when combined with the use of cryoprobes, but at the expense
of increased cost and throughput.
Mass Spectrometry in Metabolomics
The field of metabolomics has been influenced strongly by
recent developments in mass spectrometry. Mass spectrometry
provides effective and versatile analyte separation and is highly
sensitive, especially when compared to other metabolomic tech-
niques such as NMR, facilitating the analysis of hundreds, and
potentially thousands, ofmetabolite species (Schiller and Arnold,
2000). As discussed below, mass spectrometric analysis inte-
grates several distinct events, including chromatographic sepa-
ration, analyte ionization, and mass-dependent ion separation.Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc. 45
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It is possible to infuse samples directly into the mass spectrom-
eter, a technique that is sometimes described as a shotgun
approach (Han and Gross, 2005). However, most metabolomics
analyses employ an upfront chromatographic time-dependent
separation of the molecular species within each biological sam-
ple to facilitate metabolite identification and quantification.
These chromatographic processes involve a mobile solvent
phase into which the analyte mixture is dissolved. The mobile
phase passes through a column containing surfaces coated in
specific interaction chemistries, the stationary phase. The indi-
vidual chemical species dissolved within the mobile phase are
retained in the column or pass through at varying speeds, de-
pending on their interaction with the chemistry of the stationary
phase. By gradually altering the composition of the mobile
phase, the interactions between stationary phase chemistry
and analyte species can be disrupted and the analytes eluted
from the column. The chemical properties of the analyte species
result in differential retention on the stationary phase, and there-
fore separation of compounds.
The primary techniques employed are GC and LC. GC vapor-
izes the analytes and separates them in the gas phase; therefore,
it requires the analyte species to be nonpolar volatiles. A rela-
tively time-consuming and laborious prechromatography chem-
ical derivatization step is included to form volatile derivatives of
the species of interest. For example, fatty acids can be derivat-
ized to fatty acid methyl esters. By contrast, LC separates the
analyte species in the liquid phase and is therefore suited for
the analysis of thermally labile, polar, and high-molecular-mass
compounds in solution. A variety of LC column chemistries are
available, facilitating the analysis of a range of metabolites with
differing chemical properties. Nonpolar columns with carbon
chain chemistries are especially well suited for the analysis of
lipid species, whereas polar chemistries as found in hydrophilic
interaction chromatography columns are appropriate for the
separation of small, charged metabolite species such as amino
acids, nucleotides, and organic acids. The duration of chroma-
tography methods tends to be under an hr, with most analyses
lasting between 15 and 30 min per sample for each column, de-
pending on the class of metabolite measured.
Ionization
The foremost methods of analyte ionization in metabolomic
mass spectrometry are electrospray ionization (ESI) and electron
impact (EI) ionization. EI ionization is used almost exclusively in
combination with GC, as it requires the analyte to be volatile.
In EI, high-energy electrons bombard the volatile analyte,
causing it to fragment. The fragmentation generates a reproduc-
ible pattern of signals, which can be matched to spectral
databases, such as the National Institute of Standards and Tech-
nology Mass Spectral Library, for the purpose of identification.
ESI is the most commonly applied ionization technique in me-
tabolomic mass spectrometry since it facilitates ionization of
nonvolatiles in solution, making it optimal for coupling an analyt-
ical LC to a mass spectrometer for upfront molecular separation
of complex biological fluids (Wong et al., 1988). In ESI, the
analyte is eluted through a highly charged needle tip. The resul-
tant charged analyte spray droplets are heated, evaporating the
solvent and resulting in ionization, where they can then be intro-46 Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc.duced to the mass separation unit (Kebarle and Ho, 1997). The
capabilities of different ionization modes vary in their ability to
measure a range of metabolite species. In negative mode, there
is a preference for anionic species (e.g., organic acids) to ionize,
while positive mode detects neutral and cationic metabolites
(e.g., protonated amino acids and amines).
While ESI is now the backbone of MS analysis, one disadvan-
tage that occurs when analyzing complex biological molecular
mixtures is ion suppression (Petkovic et al., 2001). Ion suppres-
sion occurs when analytes compete for charge during the ioniza-
tion process, in which an individual metabolite’s ionization
efficiency is based on its chemical and physical characteristics
(Knochenmuss, 2003). Therefore, the observed relative abun-
dance for a particular ion can change, depending on the other
analytes or contaminants coionized in the matrix, even when
the interfering compound is not detected in the mass spectrum
(Wenk et al., 2003). Thus, metabolomic mass spectrometric
analysis must assume that mixtures are roughly the same among
the groups of samples analyzed. Inferences with regard to abso-
lute concentrations of metabolites across tissue matrices must
be considered preliminary. In the clinical setting, the interfering
compound could take the form of a drug present in the circula-
tion in a subset of the study population but not present in the total
population. The upfront chromatographic separation in LC and
GC prior to mass spectrometric analysis functions to reduce
ion suppression effects, but may not eliminate the problem
entirely (Peterson and Cummings, 2006).
Mass Analysis
Ionic separation in metabolomic mass spectrometry can be
achieved by a variety of techniques including time-of-flight
(TOF), quadrupole, and ion trap mass analyzers (Downard,
2004). The specifications of the analyzers vary across dynamic
range, resolution, capability for tandem MS (MS/MS), and
mass accuracy. One limitation is the direct correlation between
the resolution of an instrument and its cost. To an extent, lower
resolution and mass accuracy can be compensated for by MS/
MS capability. MS/MS is the use of two or more stages of
mass analysis to selectively examine the fragmentation of an
ion within amixture of ions (de Hoffmann 1996). MS/MS thus iso-
lates individual mass-to-charge ratio (m/z) species for fragmen-
tation. In a process known as collision-induced dissociation
(CID), the molecular ions are accelerated by an electrical poten-
tial, thereby increasing their kinetic energy. The ions then collide
with neutral gas molecules, such as helium or nitrogen, within a
collision cell in the mass spectrometer. As the molecules collide,
the kinetic energy is converted into internal energy, resulting in
the breakage of chemical bonds and the fragmentation of the
molecular ion. The fragments are then separated by m/z in a
second mass analyzer. The m/z values of the fragments aid in
the identification of the isolated ions. For example, phospholipid
headgroups give characteristic fragment patterns in the form of a
neutral loss or a specific fragment ion (Han andGross, 2005). The
speed, relative robustness, and potential for automation of this
technique have been extensively exploited. As the range of
mass spectrometers available has increased, so too has their
application to metabolomics research.
TOF instruments offer a high mass accuracy and wide m/z
range. Ions are accelerated by the application of a fixed electric
Cell Metabolism
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ion to reach a detector at the end of the flight tube is measured.
Since the electric field is fixed, all ions with the same charge gain
the same kinetic energy. However, since heavier particles travel
at a lower velocity and, conversely, lighter particles at a higher
velocity, the m/z ratio can be determined from the TOF. In me-
tabolomics experiments, it is more common to see instruments
where TOF is combined with another upfront mass analyzer,
typically a quadrupole TOF (QTOF) or an ion trap instrument as
discussed below. The upfront analyzer offers the ability to
actively select ions of interest and fragment them for the pur-
poses of identification, whereas the TOF allows for high resolu-
tion and mass accuracy.
Quadrupole mass spectrometers apply oscillating electrical
fields between four parallel rods to selectively stabilize the flight
path of ions of a particularm/z, thus serving as a mass-selective
filter. The potentials across the rods can be adjusted to sweep
across a range of m/z values or settle only on select ion masses
of interest. Although mass accuracy andm/z range are generally
inferior compared to TOF instruments, the linear dynamic range
for relative quantification is generally better with quadrupole in-
struments. Further, in triple quadrupole mass spectrometers,
the first quadrupole can act as a mass filter for select precursor
ions, the second quadrupole can be used as a collision cell to
allow CID of these precursor ions, and the third quadrupole
can either allow all fragments to pass to the detector or serve
as a mass filter for a single product fragment. Operated in the
latter mode, triple quadrupole instruments permit MS/MS spec-
trometry, with subsequent improvements in both the analytical
sensitivity and specificity for preselected analytes of interest,
which can include as many as 300 metabolites.
Ion trap mass spectrometers, which can have different struc-
tural configurations, apply an electrical field to accumulate and
hold ions of a specific m/z. Trapped metabolites can then be
ejected from the ion trap or fragmented in the ion trap for tandem
MS analysis. m/z is determined on the basis of the radio
frequency potential required to retain ions in the trap. By accu-
mulating molecules of interest, ion traps maximize analytical
sensitivity but provide less-robust quantification across a nar-
rower dynamic range.
Orbitrap mass analyzers were first described in 2000
(Makarov, 2000). The mass analyzers radially trap ions around
a central electrode. An outer electrode positioned coaxially
with the inner electrode allows m/z values to be determined
from the frequency of harmonic ion oscillations of the ions trap-
ped in orbitals. The axial frequency of the ions depends on their
energy and dispersion in space. Ion frequencies are measured
and amass spectrum obtained using fast Fourier transforms. Or-
bitraps achieve high mass resolution, high mass accuracy, and a
robust dynamic range.
Instruments that combine mass analyzers (e.g., quadrupole-
TOF and ion trap-TOF instruments) are available in which the
upstream module can be used to select and fragment ions of in-
terest and the downstream TOF component provides high-reso-
lution mass spectra. Further, alternative methodologies for m/z
discrimination are available, including Fourier transform ion
cyclotron resonance mass spectrometers. To date, these instru-
ments have been applied less frequently for human biomarker
discovery.Untargeted versus Targeted Metabolic Profiling
Both NMR and MS can be used to characterize metabolite data,
either in a targeted manner or in a nontargeted, pattern recogni-
tion manner. The approaches have their own inherent advan-
tages and disadvantages, but can be highly complementary
when used in combination. Untargeted metabolomics is the
attempt to measure all the analytes in a sample, including chem-
ical unknowns. Due to its comprehensive nature, analysis of un-
targeted metabolomic data must be conducted with advanced
chemometric techniques, such as multivariate analysis, de-
signed to reduce the extensive data sets generated into smaller,
more manageable signals. These unidentified signals then
require annotation using either in silico libraries or experimental
identification using analytical chemistry with standards. From
the perspective of biomarker discovery, untargeted analysis of-
fers the tantalizing opportunity for novel species discovery
and, therefore, the identification of unique, specific, and accu-
rate biomarkers.
In untargeted analysis, coverage of the metabolome is unbi-
ased and only restricted by the methodologies of sample prepa-
ration and the inherent sensitivity and specificity of the analytical
techniques employed. However, the untargeted approach does
suffer from a number of limitations: the protocols and time
constraints required to process the extensive raw data sets
generated, the analytical chemistry challenges of identifying
and characterizing unknown metabolites, the time demands of
identifying unknown metabolites that can run weeks and
months, the overreliance on the innate analytical coverage of
the profiling technique utilized, and a strong bias toward detec-
tion of highly abundant small molecule species can all have detri-
mental effects.
Targeted metabolomics, on the other hand, is the measure-
ment of distinct sets of characterized and chemically annotated
small molecules within a biological sample. Absolute quantifica-
tion of metabolite levels using mass spectrometry can be per-
formed via the standard addition method. Internal standards,
typically isotopically labeled versions of the endogenous metab-
olite, are spiked into the matrix across a range of concentrations
to generate a standard curve. The labeled standards, which
often contain 13C or 2H isotopes, can be easily differentiated
from the endogenous metabolite of interest due to the isotopic
difference in mass. It is also imperative that the isotope-labeled
standard is pure to avoid interference with, and modulation of,
the endogenous metabolite signal. The targeted approach ex-
ploits the extensive a priori knowledge of a vast array of metab-
olites and the metabolic pathways to which they belong in order
to select specific species for analysis. By analyzing specific key
metabolites across all characterized metabolic pathways, these
metabolites can function as sentinels to identify perturbations in
the pathways, highlighting them for further analysis. When
performing targeted metabolomics on a mass spectrometer,
the instrument is more sensitive since it is measuring fewer com-
pounds. Furthermore, the sample preparation step can bemodi-
fied to reduce the overrepresentation of abundant molecules in
the analyses. From a biomarker perspective, this can facilitate
the association of low-abundance metabolites with disease
states. While their unambiguous identification is known a priori,
their association with a given phenotype may be novel. If a
particular pathway appears to be highlighted in the analyses,Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc. 47
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spectrometric metabolomic assay for a more detailed interroga-
tion. In addition, since all analyzed species are clearly defined,
analytical artifacts are not carried through to downstream ana-
lyses, and laborious chemical classification steps are not
required.
Applications of Metabolomics for Biomarker Discovery
In an initial proof of principle study, Newgard and colleagues pro-
filed obese versus lean humans to gain a broad understanding of
the metabolic and physiological differences in these two dispa-
rate groups. Their studies identified a branched-chain amino
acid (BCAA) signature that was highly correlated with metrics
of insulin resistance (Newgard et al., 2009). In complementary
studies in two large, population-based cohorts, branched-chain
and aromatic amino acid concentrations were demonstrated to
have a significant association with future type 2 diabetes up to
12 years before the onset of overt disease (Wang et al.,
2011a). These findings were essentially unchanged after adjust-
ment for established clinical risk factors. The initial discovery
experiment utilized a nested, case-control design in the Fra-
mingham Heart Study, with approximately 200 individuals that
ultimately developed DM and a similar number of control individ-
uals that were matched for age, body mass index, and fasting
glucose that did not develop DM. A validation experiment in
the Malmo¨ Diet and Cancer Study employed the same matching
scheme. Since the study design enriched the control population
for high-risk features, such as obesity and increased fasting
glucose, analyses were also performed on randomly selected
controls. In a distinct study, similar findings were obtained in a
much larger population of Finnish men (Stanca´kova´ et al.,
2012). Although the association between metabolites and inci-
dent diabetes was significant across each experiment, the
strength of association was attenuated in the case versus
random cohort analysis. Whereas amino acid increases led to
large improvements in model fit and discrimination (c-statistics)
between cases and matched controls, changes in these param-
eters were less significant between cases and random controls.
These findings suggest that amino acid profiling might have
greater value in high-risk individuals and underscore how study
design modulates study outcome and interpretation. Although
metabolomics technologies are new, old lessons in epidemi-
ology still apply.
Limitations to Human Biomarker Studies
Several limitations to metabolomic biomarker discovery efforts
in humans warrant consideration. While serum or plasma
samples from peripheral blood are easily obtained or already
available in many cohorts, the circulation integrates the inputs
of multiple organ systems, making the source of a given signal
difficult to ascertain. It is notable, however, that metabolomics
profiling can measure metabolites in plasma typically thought
to be confined to intracellular compartments based on their
phosphorylation state or site of bioactivity. For example, while
intracellular tricarboxylic acid (TCA) cycle and adenine nucleo-
tide changes in muscle during exercise are well characterized
from animal tissues or even human tissue punch biopsies,
high-sensitivity LC-MS platforms have also been used to
examine whether these changes occur in plasma in a fitness-48 Cell Metabolism 18, July 2, 2013 ª2013 Elsevier Inc.dependent way (Lewis et al., 2010). In certain unique human
conditions, selective catheterization across tissue beds can be
performed (for example, by simultaneously acquiring coronary
sinus or pulmonary artery and peripheral arterial blood samples).
Of course, some metabolic abnormalities in a given tissue bed
may remain silent in the peripheral blood until severe organ
dysfunction has occurred.
Although capable of generating metabolic snapshots, metab-
olite profiling of clinical plasma samples does not provide infor-
mation on pathway flux. For example, it is unable to determine
whether a metabolite is increased because it is being produced
in excess or because of a downstream inhibition. To unambigu-
ously define the rate of flux of a metabolic pathway, stable
isotope-labeled substrates can be employed (Roberts et al.,
2011). In flux analysis, the incorporation of the label (for example,
13C) into metabolites downstream of the labeled substrate in a
metabolic pathway can be measured using mass spectrometry
or NMR to determine the metabolic rate.
Further, the development of clinically useful biomarkers will
require amore comprehensive understanding of how exogenous
factors impact the metabolome (e.g., how do diet and medica-
tions impact metabolite markers of interest, and what is the
normal intra- and interindividual variability for these metabo-
lites?). Finally, although adequately powered clinical studies
enable strategies to minimize confounding (e.g., multivariable
adjustment or population stratification by known risk factors),
they are unable to establish a causal link between disease bio-
markers and disease pathogenesis.
While a growing number of studies have usedmass spectrom-
etry as a tool for biomarker discovery, many of the studies have
been cross-sectional, providing limited information regarding the
relation of metabolomic (or proteomic) biomarkers to the future
development of disease. Long periods of observation are also
important features of a good study design because it enables in-
vestigators to identify changes in metabolites that occur well
before any secondary alteration from the overt disease process.
From Association to Causation: Integrating Human and
Animal Studies
To investigate causal relationships, metabolomic findings
derived in human studies can be further interrogated in model
systems. Studies in rodents have extended the clinical observa-
tions of elevated branched-chain amino acids in prediabetes. To
test the impact of BCAA on metabolism, Newgard and col-
leagues placed rats on diets consisting of standard chow, high
fat, or high fat supplemented with BCAA (Newgard et al.2009).
Despite having food intake and weights equivalent to the stan-
dard chow group, high-fat and BCAA-fed mice were as insulin
resistant as the high-fat-fed animals. The underlying cellular
mechanisms may include activation of the mammalian target
of rapamycin (mTOR), JUN, and insulin receptor substrate 1
(IRS1) signaling pathways in skeletal muscle. While not all
studies of branched-chain amino acid supplementation in mu-
rine systems have led to identical results, future exploration of
this pathway is clearly warranted.
In a translational study utilizing nontargeted LC-MS-based
metabolite profiling, Wang et al. (2011b) first profiled plasma
from 75 individuals from a hospital-based cohort who experi-
enced a myocardial infarction, stroke, or death in the ensuing
Cell Metabolism
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not. Of 18 analytes that were significantly different between
cases and controls, 3 demonstrated significant correlations
among one another, suggesting a potential common biochem-
ical pathway. Using complementary analytical methods, these
metabolites were identified as betaine, choline, and trimethyl-
amine N-oxide, all metabolites of dietary phosphatidylcholine.
Dietary supplementation of choline was sufficient to promote
atherosclerosis in mice, and suppression of intestinal bacteria
responsible for the conversion of phosphatidylcholine to choline
inhibited this atherogenesis. In addition to reinforcing the inter-
action between diet, gut bacteria, and the metabolome, this
study demonstrates how metabolomic biomarker discovery
can elucidate novel pathways to disease.
From Association to Causation: Integrating Genetic
Findings
Integrating genomic and metabolomic data in humans repre-
sents an alternative strategy to establish a causal link between
metabolite biomarkers and disease. For a biomarker that has a
causal role, the expected random distribution in a population
of a polymorphism that determines high or low biomarker con-
centrations would be skewed in individuals depending on their
disease status. The association between a disease or a metab-
olite and a genetic polymorphism that mimics the biological
link between a proposed exposure and disease is not
confounded by the reverse causation affecting many epidemio-
logical observational studies. Data from so-called Mendelian
randomization studies are accumulating for several biomarkers.
Analyses demonstrating that single-nucleotide polymorphisms
(SNPs) that modulate plasma low-density lipoprotein (LDL)
cholesterol concentrations are independently associated with
incident cardiovascular disease are consistent with the known
causal role LDL cholesterol plays in atherogenesis (Kathiresan
et al., 2008). By contrast, genetic loci associated with plasma
C-reactive protein concentrations (including in the CRP locus)
had no association with coronary heart disease, arguing against
a causal association between C-reactive protein and cardiovas-
cular disease (Elliott et al., 2009).
Recent work has begun to explore the genetic determinants
of plasma metabolite levels in large human cohorts. One of the
first publications to successfully combine genome-wide associ-
ation studies (GWAS) with metabolomics analyzed 363 metab-
olites in fasting serum from 284 males enrolled in the Cooper-
ative Health Research in the Region of Augsburg (KORA) Study
using LC-MS (Gieger et al., 2008). GWAS analysis of these in-
dividuals demonstrated that associations between SNPs and
metabolite concentrations accounted for 12% of the observed
variance in metabolism overall. In a larger-scale study of 1,809
individuals also from the KORA Study, Illig et al. (2010) com-
bined GWAS with an LC-MS-based metabolomics analysis of
169 serum metabolites to demonstrate that SNPs located in
or near a range of genes accounted for 5.6%–36.3% of vari-
ance in metabolite concentrations. The data were validated in
a population of 422 individuals from the TwinsUK Study. This
approach has also been applied to the urine metabolome.
Suhre et al. (2011) published a study analyzing GWAS in rela-
tion to 59 metabolite concentrations measured by NMR in urine
samples from two large cohorts. Many of the findings in thesestudies highlight locus-metabolite associations with strong bio-
logical plausibility. For example, the locus of interest includes a
gene encoding a protein directly responsible for the meta-
bolism or transport of the given metabolite. However, many
other locus-metabolite associations have been identified in
these studies without a clear biochemical relationship with
the given metabolite, providing strong motivation for future
investigation, particularly when the metabolite of interest is
associated with a disease phenotype. An alternative approach
that can be taken is to begin with disease-associated SNPs
and then integrate the NMR or MS data to begin to understand
the metabolic consequences of the human variant of interest.
Despite these advances, however, convincing links between
SNPs, metabolite levels, and disease states remain to be
validated. As ongoing studies further delineate the genetic
determinants of plasma metabolite profiles, efforts to triangu-
late gene-metabolite-disease associations will provide insight
into if and how metabolite markers contribute to disease
pathogenesis.
Conclusions
Emerging technologies now permit higher-resolution phenotyp-
ing of biological specimens. Whereas robust technologies
capable of genomic and transcriptomic profiling are nowwell es-
tablished, no single analytical method provides comprehensive
coverage of the human metabolome. Thus, investigators have
employed various technologies, including NMR and MS
(coupled to either upfront LC or GC), and utilized alternative
analytical strategies (i.e., targeted versus pattern recognition).
Metabolite profiling has demonstrated feasibility in large epide-
miologic human cohorts. However, further efforts to understand
the diversity of inputs to the metabolome will be an important
resource for future metabolomic biomarker studies. In parallel,
investigation in model systems and integration with other func-
tional genomic approaches in humans will provide insight into
the pathophysiologic interactions between metabolite markers
and disease.
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